Literature DB >> 11294418

The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma.

Y B Park1, H S Kim, J H Oh, S H Lee.   

Abstract

Multidrug resistance (MDR), mediated by P-glycoprotein (P-gp), is an in vitro phenomenon observed within tumour cells, suggesting cross-resistance to unrelated drugs, and expression of P-gp may therefore affect the prognosis and incidence of recurrence after treatment. The mutant p53 protein causes reduced tumour suppression. Co-expression of p53 and P-gp is related to short survival, increased tumour activity and drug resistance. The purpose of this study was to measure the expression of p53 protein and P-gp in osteosarcoma tissue and assess its prognostic significance. Fifty-two tumour specimens were evaluated. The correlation between p53 and P-gp expression was significant (P=0.0008). In univariate analysis of survival, p53 protein was not significant (P=0.2) but P-gp was significant (P=0.0001). The co-expression of p53 and P-gp was the strongest indicator of a short survival according to multivariate analysis (P=0.0004).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294418      PMCID: PMC3619924          DOI: 10.1007/s002640000196

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  16 in total

1.  Seeding of osteosarcoma in the biopsy tract of a patient with multifocal osteosarcoma.

Authors:  Kriengkrai Iemsawatdikul; Charles A Gooding; Elisabeth L Twomey; Grace Eun Hye Kim; Robert E Goldsby; Inbal Cohen; Richard J O'Donnell
Journal:  Pediatr Radiol       Date:  2005-03-09

2.  Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping.

Authors:  N Entz-Werle; A Schneider; C Kalifa; A-C Voegeli; M-D Tabone; P Marec-Berard; L Marcellin; H Pacquement; P Terrier; P Boutard; N Meyer; M-P Gaub; P Lutz; A Babin; P Oudet
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

3.  Nuclear Protein Phosphatase 1 α (PP1A) Expression is Associated with Poor Prognosis in p53 Expressing Glioblastomas.

Authors:  Arun H Shastry; Balaram Thota; Mallavarapu R Srividya; Arimappamagan Arivazhagan; Vani Santosh
Journal:  Pathol Oncol Res       Date:  2015-08-09       Impact factor: 3.201

4.  Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes.

Authors:  Joshua E Allen; Lori S Hart; David T Dicker; Wenge Wang; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2009-11-27       Impact factor: 4.742

Review 5.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

6.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

7.  Molecular mechanisms of chemoresistance in osteosarcoma (Review).

Authors:  Hongtao He; Jiangdong Ni; Jun Huang
Journal:  Oncol Lett       Date:  2014-03-04       Impact factor: 2.967

Review 8.  Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.

Authors:  Tang Liu; Zhihong Li; Qing Zhang; Karen De Amorim Bernstein; Santiago Lozano-Calderon; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Oncotarget       Date:  2016-12-13

9.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25

10.  Decreased local and systemic levels of sFRP3 protein in osteosarcoma patients.

Authors:  Dalibel Bravo; Ahmet Salduz; Kristen L Shogren; Madison N Okuno; James L Herrick; Scott H Okuno; Mario Galindo; Andre J van Wijnen; Michael J Yaszemski; Avudaiappan Maran
Journal:  Gene       Date:  2018-06-19       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.